Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20136-2 in Healthy/Obese Participants
NCT07716241Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing HS-20136-2 with Placebo (2 arms). Primary endpoint: Number of Adverse Events at 112 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
HS-20136-2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07716241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716241.